Want a Steroid-Sparing Claim on Your Label? Start Here
Chronic glucocorticoid exposure, even at low doses, is now seen by regulators and clinicians as an unacceptable safety burden. Sponsors that prioritize steroid-toxicity from the outset position ...
In Conversation With… Kathy Perez
“When patients can track their own experience of steroid‑toxicity and take that data straight into the clinic, they stop being passive recipients and start driving the conversation.” Clinicians know ...
Sam Usage Data Shows Surge in User Adoption
New data presented at EULAR 2025 show Sam’s rapid user growth and increasing importance to patients. At the American College of Rheumatology (ACR) Annual Meeting in Washington, DC, Steritas released ...
In Conversation With… Albert Whangbo, PhD
“Steroids are cheap and effective in the short term. Convincing payers that steroid-sparing therapies are worth the upfront cost is still a practical challenge.” Albert Whangbo, PhD, leads the global ...
Academic Uptake of Steritas STOX Suite Expands Across Trials and Institutions
Academic institutions worldwide are increasingly adopting the clinical outcome assessments (COA) of steroid-toxicity that make up the STOX® Suite from Steritas. To date, 26 academic licenses are in ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
